Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

258
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
258
Lipid Absorption01:24

Lipid Absorption

2.3K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.3K
Lipid Digestion01:06

Lipid Digestion

98.2K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
98.2K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

491
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
491
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.7K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta-Blocker Discontinuation After Myocardial Infarction: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

Beta-Blocker Discontinuation in Acute Heart Failure: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

Pharmacotherapy for mild hypertension.

The Cochrane database of systematic reviews·2026
Same author

CT-derived optic nerve sheath diameter as a noninvasive proxy for intracranial pressure in traumatic brain injury patients undergoing preoperative ICP monitoring: An institutional analysis and scoping review.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

Pharmacotherapy for hypertension in adults 60 years or older.

The Cochrane database of systematic reviews·2025
Same author

Pharmacotherapy for mild hypertension.

The Cochrane database of systematic reviews·2025
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Dec 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Pitavastatin for lowering lipids.

Stephen P Adams1, Nima Alaeiilkhchi2, James M Wright1

  • 1Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada.

The Cochrane Database of Systematic Reviews
|June 20, 2020
PubMed
Summary
This summary is machine-generated.

Pitavastatin effectively lowers LDL cholesterol, total cholesterol, and triglycerides in a dose-dependent manner. This statin demonstrates significant potency compared to other lipid-lowering drugs.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.5K

Related Experiment Videos

Last Updated: Dec 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.5K

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism
  • Evidence-Based Medicine

Background:

  • Pitavastatin is a recently introduced statin.
  • The dose-response relationship for pitavastatin's lipid-lowering effects requires clarification.

Purpose of the Study:

  • To quantify the effects of various pitavastatin doses on lipid markers (LDL cholesterol, total cholesterol, HDL cholesterol, triglycerides).
  • To compare pitavastatin's efficacy against other statins.
  • To assess pitavastatin's dose-related impact on adverse event withdrawals.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and controlled before-and-after studies.
  • Searched multiple databases (CENTRAL, MEDLINE, Embase) up to March 2019.
  • Assessed risk of bias for included studies.

Main Results:

  • Forty-seven studies involving 5436 participants were analyzed.
  • Pitavastatin demonstrated a linear, dose-dependent reduction in LDL cholesterol, total cholesterol, and triglycerides.
  • For every doubling of the pitavastatin dose, LDL cholesterol decreased by 5.35%, total cholesterol by 3.93%, and triglycerides by 3.76%.
  • Pitavastatin showed significant potency in lowering LDL cholesterol compared to atorvastatin, rosuvastatin, and fluvastatin.
  • No dose-related effect was observed on HDL cholesterol, which increased by an average of 4%.

Conclusions:

  • Pitavastatin effectively lowers blood lipids in a dose-dependent linear fashion.
  • Pitavastatin exhibits superior potency in LDL cholesterol reduction compared to several other statins.
  • Insufficient data were available to determine the risk of adverse event withdrawals associated with pitavastatin.